Corporation
AstraZeneca Canada Inc.
- Meetings this Parliament
- 63
- With MPs
- 19
- Since Nov 2021
- 134
- Active registrations
- 1
Most recent reported meeting: Aug 28, 2026.
Lobbying by AstraZeneca Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since May 11, 2026
Filed by Gaby Bourbara, President
Lobbyists
- Alex Romanovschi · Vice President, Scientific Affairs
- Carlo Mastrangelo · Head - Corporate Communications - Corporate Affairs Canada
- Deb Wong · Director, Payer Engagement
- Denise Lacombe · Head of Legal
- Gena Restivo · VP, Corporate Affairs & Sustainability
- Heather McDonald · Vice President, Market Access and Pricing
- Isabelle Gagnon · Lead - Federal Government Affairs
- Jon Feairs · Director, Government Affairs & Public Policy
- Noel Saraza · Senior Manager, Payer Relations
- Pascal Soriot · Chief Executive
- Tharany Ganesh · Head of Regulatory Affairs
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (14)Hide details
- Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
- Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
- Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
- Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
- Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
- Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Registration 957438-15042-67. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Gaby Bourbara (91), Kiersten Combs (43).
-
Reported by Kiersten Combs · In-house (corporation)
- Hilary Peirce · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
HealthIndustry
-
Reported by Kiersten Combs · In-house (corporation)
- Sadenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Jean-Sébastien Bock · Director of Policy, Health Canada (HC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Ed Fast · Member of Parliament, House of Commons
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Kiersten Combs · In-house (corporation)
- Kirsty Duncan · Member of Parliament, House of Commons
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Kiersten Combs · In-house (corporation)
- Martin Montreuil · Director, Public Services and Procurement Canada (PSPC)
- Mario Dicaire · Senior Manager, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by Kiersten Combs · In-house (corporation)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
- Milan Patel · Senior Manager, Public Services and Procurement Canada (PSPC)
HealthScience and Technology
-
Reported by Kiersten Combs · In-house (corporation)
- Bersabel Ephrem · DIrector General, Public Health Agency of Canada (PHAC)
- Jacqueline Arthur · Assistant Executive Director, Public Health Agency of Canada (PHAC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Pierre Sabourin · Assistant Deputy Minister, Health Canada (HC)
- Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)
- Nancy Hamzawi · Federal Lead and Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.